A5063505202- Sepsis Diagnosis and Treatment
- Viral Infections and Vectors
- Hemophilia Treatment and Research
- Clinical Nutrition and Gastroenterology
- Tuberculosis Research and Epidemiology
- Viral Infections and Outbreaks Research
- Platelet Disorders and Treatments
- Intensive Care Unit Cognitive Disorders
- Nosocomial Infections in ICU
- Mycobacterium research and diagnosis
- Pneumonia and Respiratory Infections
- Respiratory Support and Mechanisms
- Heme Oxygenase-1 and Carbon Monoxide
- Blood Coagulation and Thrombosis Mechanisms
- Airway Management and Intubation Techniques
- Immune Response and Inflammation
- Fire effects on ecosystems
- Medical Imaging and Pathology Studies
- Child Nutrition and Feeding Issues
- Infectious Diseases and Tuberculosis
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Pneumocystis jirovecii pneumonia detection and treatment
- Chronic Myeloid Leukemia Treatments
- Neonatal Health and Biochemistry
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
Hillhurst Biopharmaceuticals (United States)
2017-2022
Catalyst Biosciences (United States)
2016-2021
Zimmer Biomet (Switzerland)
2018
Bellerophon Therapeutics (United States)
2016
Beth Israel Deaconess Medical Center
2016
University of Iowa
2016
Cedars-Sinai Medical Center
2016
Massachusetts General Hospital
2016
Clinical Research Institute
2016
University of the Witwatersrand
1986-2007
In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis a high risk of death. The FDA required study to evaluate efficacy DrotAA low death.We randomly assigned adult patients with death (defined by an Acute Physiology Chronic Health Evaluation [APACHE II] score <25 or single-organ failure) receive intravenous infusion placebo (24 microg per kilogram body weight hour) 96 hours in double-blind, placebo-controlled,...
To determine the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in treatment patients with severe sepsis.Prospective, randomized, double-blind, placebo-controlled, multicenter trial a planned, midstudy, interim analysis.Ninety-one academic medical center intensive care units North America Europe.Patients sepsis or septic shock (n = 696) received standard supportive antimicrobial therapy for sepsis, addition to rhIL-1ra placebo.Patients were...
To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in treatment patients with sepsis syndrome.Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial.A total 31 hospitals United States Canada.There were 994 syndrome enrolled this trial, 971 infused study drug.Patients prospectively stratified into shock or nonshock groups then randomized to receive a single infusion 15 mg/kg TNF-alpha MAb, 7.5 placebo....
To determine the safety and efficacy of recombinant thrombomodulin (ART-123) in patients with suspected sepsis-associated disseminated intravascular coagulation.Phase 2b, international, multicenter, double-blind, randomized, placebo-controlled, parallel group, screening trial.Two hundred thirty-three ICUs 17 countries.All adult admitted sepsis coagulation as assessed using a modified International Society on Thrombosis Hemostasis score.Patients were randomized to receive IV ART-123 (0.06...
Objective To assess the effects of drotrecogin alfa (activated) therapy, a recombinant human activated protein C, across clinically relevant subpopulations in randomized, phase 3, placebo-controlled study patients with severe sepsis (recombinant C worldwide evaluation [PROWESS]). Design Univariate and multivariable analysis prospectively defined subgroups from PROWESS study. Setting A total 164 medical centers 11 countries. Patients 1,690 sepsis. Measurements Main Results We report observed...
Objective: To investigate community-acquired pneumonia (CAP) as a cause of severe sepsis in the PROWESS (Recombinant Human Activated Protein C Worldwide Evaluation Severe Sepsis) trial and to evaluate effect drotrecogin alfa (activated) (DrotAA) this subgroup. Design: Retrospective analysis CAP subgroup trial. Setting: Tertiary care institutions 11 countries. Interventions: DrotAA (n = 850), 24 μg·kg−1·hr−1 for 96 hrs, or placebo 840). Participants: The 1,690 patients with enrolled...
Objective To describe the clinical characteristics of a group patients infected with newly recognized hantavirus in Southwestern United States. Design Case series. Setting Tertiary referral center. Patients All confirmed infection admitted to University New Mexico Hospital between May 1, 1993 and January 1994. Interventions Records were reviewed collect all pertinent data. Measurements Main Results Pulmonary disease these was characterized by hypoxemia covering wide range severity. The cause...
Clinical trials with novel therapeutic agents for severe sepsis have suggested that patients might respond differently depending on causative microorganism. Data from a large, placebo-controlled trial of recombinant human drotrecogin alfa (activated) (DrotAA) were analyzed by type microorganism treatment-associated differences in mortality, coagulopathy, and inflammatory response. Compared placebo, mortality rates associated DrotAA consistently reduced each group (gram-positive bacteria,...
Acute kidney injury (AKI) is common in critically ill patients with severe sepsis (SS), and the predictors of AKI this population have not been well characterized. The study group was placebo Prospective Recombinant Human Activated Protein C Worldwide Evaluation Severe Sepsis (PROWESS) data set. PROWESS a prospective, randomized, controlled use drotrecogin alpha (activated) for treatment SS. Placebo who had an admission renal organ failure score 2 or more were excluded. defined as increase...
BACKGROUND. Ribavirin is active in vitro against hantaviruses, but the findings of an open trial use intravenous ribavirin for treatment hantavirus cardiopulmonary syndrome (HCPS) were inconclusive.Subjects with suspected HCPS prodrome or phase without shock eligible randomization to receive either (33 mg/kg [<or=2 g], followed by 16 [<or=1 g] given every 6 h 4 days and 8 [<or=.5 3 days) placebo (administered 7 until initial Sin Nombre virus antibody test result was confirmed be negative)....
Agonism of protease-activated receptor (PAR) 1 by activated protein C (APC) provides neuro- and vasculoprotection in experimental neuroinjury models. The pleiotropic PAR1 agonist, 3K3A-APC, reduces neurological injury promotes vascular integrity; 3K3A-APC proved safe human volunteers. We performed a randomized, controlled, blinded trial to determine the maximally tolerated dose (MTD) ischemic stroke patients.
1. Introductory .—This is the third of a series papers dealing with stability or instability certain forms vortex motion associated wake body moving in fluid. In earlier we examined case system equal rings parallel planes, as they might form rear sphere steady motion. Nisi and Porter have shown that lowest speed at which ring 8·14 v / d where kinematic viscosity fluid diameter sphere. Such vortices has been proved to be only partially stable, it therefore inferred their production occurs...
Objective To evaluate the safety and efficacy of an intravenous liposomal dispersion prostaglandin E1 as TLC C-53 in treatment patients with acute respiratory distress syndrome (ARDS). Design Randomized, prospective, multicenter, double-blind, placebo-controlled, phase III clinical trial. Setting Forty-seven community university-affiliated hospitals United States. Patients A total 350 ARDS were enrolled this Intervention prospectively randomized a 1:1 ratio to receive either or placebo. The...
Background: Patients with community-acquired pneumonia (CAP) comprised 35.6% of the overall phase 3 Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study and 33.1% placebo arm. We investigated use CURB-65, Pneumonia Severity Index (PSI), Acute Physiology Chronic Health II (APACHE II) prediction scores to identify CAP population from PROWESS arm at greatest mortality risk. Methods: were classified as having if lung was primary infection site patient...
A system of equal circular vortex filaments have their centres evenly spaced along a straight line, and planes at right angles to this line. The present investigation is concerned with the stability or instability such an arrangement. corresponding problem in two dimensions has been dealt by Kármán who considered case infinite trails parallel rectilinear vortices, object applying his results resistance cylinder moving fluid state motion rear cylinder. filaments, on other hand, may be...